Biotech / Finance

Editas Get A Vetr Upgrade To Strong Buy

From Biotech
March 20, 2017 - 4:51pm
The Vetr crowd Monday upgraded their rating for Editas Medicine Inc (NASDAQ: EDIT), from 4 stars (Buy), issued 313 days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish. Editas has traded fairly sporadically over the course of March, which began with the stock entering a trough of over 18 percent to a low of ...Full story available on

Continue reading this article »